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BACKGROUND
In patients with stable angina, two strategies are often used to guide revascularization: 
one involves myocardial-perfusion cardiovascular magnetic resonance imaging (MRI), 
and the other involves invasive angiography and measurement of fractional flow re-
serve (FFR). Whether a cardiovascular MRI–based strategy is noninferior to an FFR-
based strategy with respect to major adverse cardiac events has not been established.
METHODS
We performed an unblinded, multicenter, clinical-effectiveness trial by randomly as-
signing 918 patients with typical angina and either two or more cardiovascular risk 
factors or a positive exercise treadmill test to a cardiovascular MRI–based strategy or 
an FFR-based strategy. Revascularization was recommended for patients in the cardio-
vascular-MRI group with ischemia in at least 6% of the myocardium or in the FFR 
group with an FFR of 0.8 or less. The composite primary outcome was death, nonfatal 
myocardial infarction, or target-vessel revascularization within 1 year. The noninferior-
ity margin was a risk difference of 6 percentage points.
RESULTS
A total of 184 of 454 patients (40.5%) in the cardiovascular-MRI group and 213 of 464 
patients (45.9%) in the FFR group met criteria to recommend revascularization (P = 0.11). 
Fewer patients in the cardiovascular-MRI group than in the FFR group underwent index 
revascularization (162 [35.7%] vs. 209 [45.0%], P = 0.005). The primary outcome occurred 
in 15 of 421 patients (3.6%) in the cardiovascular-MRI group and 16 of 430 patients 
(3.7%) in the FFR group (risk difference, −0.2 percentage points; 95% confidence inter-
val, −2.7 to 2.4), findings that met the noninferiority threshold. The percentage of pa-
tients free from angina at 12 months did not differ significantly between the two groups 
(49.2% in the cardiovascular-MRI group and 43.8% in the FFR group, P = 0.21).
CONCLUSIONS
Among patients with stable angina and risk factors for coronary artery disease, myo-
cardial-perfusion cardiovascular MRI was associated with a lower incidence of coronary 
revascularization than FFR and was noninferior to FFR with respect to major adverse 
cardiac events. (Funded by the Guy’s and St. Thomas’ Biomedical Research Centre of 
the National Institute for Health Research and others; MR-INFORM ClinicalTrials.gov 
number, NCT01236807.)
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Management of the care of pa-tients with stable coronary artery dis-ease is based on reduction of risk fac-
tors, guideline-directed medical therapy, and 
revascularization in those with persistent symp-
toms or proven ischemia.1,2 In symptomatic pa-
tients with risk factors for coronary artery dis-
ease, two strategies are predominantly used to 
establish the diagnosis and guide management 
of care. The first uses invasive angiography visual-
izing the presence and distribution of coronary 
artery disease, supported by assessment of frac-
tional flow reserve (FFR) to guide the need for 
subsequent revascularization.3,4 The second uses 
noninvasive functional stress testing, followed 
by invasive angiography and revascularization in 
patients with a positive test. International guide-
lines differ in their recommendations for non-
invasive testing.1,2 However, there is consensus 
that revascularization should be guided by ische-
mia testing5 unless the left main coronary artery 
is involved.6
Myocardial-perfusion cardiovascular magnet-
ic resonance imaging (MRI) is a noninvasive test 
for the detection of coronary artery disease that 
has a high concordance with FFR for ischemia 
detection.7-9 Cardiovascular MRI has been asso-
ciated with a lower incidence of invasive angiog-
raphy than testing based on clinical risk assess-
ment.10 However, data are lacking on the 
effectiveness of a cardiovascular MRI–based 
strategy to guide coronary revascularization as 
compared with an invasive angiography–based 
strategy. We hypothesized that an initial man-
agement strategy based on myocardial-perfusion 
cardiovascular MRI would be noninferior to a 
strategy guided by invasive angiography and FFR 
in terms of major adverse cardiac events.
Me thods
Trial Design and Oversight
The Myocardial Perfusion CMR versus Angiog-
raphy and FFR to Guide the Management of 
Patients with Stable Coronary Artery Disease 
(MR-INFORM) trial was an unblinded, investigator-
led, international, multicenter, comparative-effec-
tiveness, noninferiority trial involving patients 
with symptoms of stable angina and risk factors 
for coronary artery disease. The trial design and 
methods have been published previously.11 The 
trial was approved by the United Kingdom Na-
tional Research Ethics Service and local institu-
tional review boards. Oversight of trial conduct 
was provided by the Joint Research Office of 
Guy’s and St. Thomas’ Hospital and King’s Col-
lege London.
Trial investigators and committees are pre-
sented in the Supplementary Appendix, available 
with the full text of this article at NEJM.org. An 
independent data and safety monitoring board 
monitored the progress of all aspects of the trial. 
An independent clinical-research organization 
(Pharmtrace, Berlin) oversaw the data manage-
ment and quality, as well as the safety and effi-
cacy outcomes. After database closure, an inde-
pendent trial statistician analyzed the data. All 
procedures were carried out in accordance with 
Good Clinical Practice guidelines and the prin-
ciples of the Declaration of Helsinki.
Funding was provided by the Guy’s and St. 
Thomas’ Biomedical Research Centre of the Na-
tional Institute for Health Research, United King-
dom, and the German Center for Cardiovascular 
Research, with supplemental corporate support 
from Bayer, Germany, as an unrestricted grant 
payable to King’s College London. Funders had 
no role in the design of the trial; the collection, 
analysis or interpretation of the data; or the 
writing and review of the manuscript. The au-
thors vouch for the completeness and accuracy 
of the data and for the fidelity of the trial to the 
protocol (available at NEJM.org).
Trial Population
Patients were enrolled at 16 sites in the United 
Kingdom, Portugal, Germany, and Australia 
(Table S1 in the Supplementary Appendix). Pa-
tients 18 years of age or older with typical angina 
symptoms (Canadian Cardiovascular Society 
[CCS] class II or III angina, with classes ranging 
from I to IV and higher classes indicating great-
er limitations on physical activity due to angina) 
and either two or more cardiovascular risk fac-
tors (smoking, diabetes, hypertension, hyperlip-
idemia, or a family history of coronary artery 
disease) or a positive exercise treadmill test were 
included. No systematic effort was made to 
maximize medical therapy for angina before 
screening for enrollment. Exclusion criteria were 
contraindications to adenosine myocardial-perfu-
sion cardiovascular MRI,11 cardiac arrhythmias 
(atrial fibrillation or frequent ectopic beats of 
>20 per minute), a known left ventricular ejec-
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tion fraction of less than 30%, New York Heart 
Association class III or IV heart failure (with 
classes ranging from I to IV and higher classes 
indicating greater disability), previous coronary-
artery bypass grafting (CABG), percutaneous 
coronary intervention (PCI) within 6 months, or 
an estimated glomerular filtration rate of less 
than 30 ml per minute per 1.73 m2 of body-
surface area. All the patients provided written 
informed consent.
Management Strategy
Patients were randomly assigned in a 1:1 ratio to 
the cardiovascular-MRI group (guideline-directed 
medical therapy and revascularization guided by 
myocardial-perfusion cardiovascular MRI) or the 
FFR group (guideline-directed medical therapy 
and revascularization guided by invasive angiog-
raphy with measurement of FFR). Randomization 
was performed with fixed block sizes, stratified 
according to center and sex within center. All 
the randomly assigned diagnostic tests were 
performed and interpreted by senior local physi-
cians, who made all subsequent clinical man-
agement decisions.
Patients assigned to the FFR group under-
went invasive coronary angiography and FFR 
testing in all coronary arteries with a caliber of 
2.5 mm or more and a stenosis severity of 40% 
or more, if technically feasible. Total occlusions 
were deemed to be FFR-positive. Details of the 
FFR procedure have been described previously.11 
Revascularization was recommended in all ves-
sels with an FFR of 0.8 or less. The decision to 
proceed to PCI or CABG was made in line with 
practice guidelines.1 Patients in this group also 
underwent a cardiovascular MRI study (including 
assessment of myocardial perfusion) before the 
invasive study. This scan was not reported, and 
all results were blinded.
In the cardiovascular-MRI group, myocardial-
perfusion cardiovascular MRI was performed 
with the use of scanners that had a magnetic 
field strength of 1.5 Tesla; the scanner vendors 
at each site are listed in Table S1 in the Supple-
mentary Appendix. The cardiovascular MRI pro-
tocol has been described previously.11 In brief, 
myocardial perfusion was assessed with the first 
pass of gadobutrol (in the form of Gadovist, 
from Bayer, Leverkusen, Germany) at a dose of 
0.075 mmol per kilogram of body weight during 
adenosine infusion at a rate of 140 to 210 μg per 
kilogram per minute for up to 6 minutes, fol-
lowed by assessment of resting perfusion after 
10 minutes and scar imaging. Clinically signifi-
cant inducible ischemia was defined as involving 
any of the following: two or more neighboring 
segments, two adjacent slices, or a single trans-
mural segment (approximately 6% of the myo-
cardium).11 Ischemic burden was calculated semi-
quantitatively, as described in the Supplementary 
Appendix. Patients with clinically significant in-
ducible ischemia underwent invasive angiogra-
phy, and revascularization was recommended, 
guided by the localization of the ischemic terri-
tory. The final decision on need for and type of 
revascularization and the target vessel or vessels 
was left to the performing interventional cardi-
ologist. FFR was not permitted in this group.
All the patients undergoing coronary revascu-
larization received dual antiplatelet therapy. All 
the patients and their health care providers re-
ceived protocol-directed guidance on guideline-
directed medical therapy, treatment targets, and 
lifestyle advice (see the Supplementary Appen-
dix). In the case of persistent chest pain, anti-
anginal therapy was increased. Subsequent inva-
sive angiography was performed at the discretion 
of the responsible physician for patients with 
refractory symptoms.
The quality of the cardiovascular-MRI and 
FFR studies was assessed in a randomly selected 
10% of cases by the first author (for cardiovas-
cular MRI) or the Glasgow Coronary Physiology 
Core (for FFR). The quality and completeness of 
data entry were monitored with a combination 
of site visits and remote monitoring. A subgroup 
of patients received a second cardiovascular-MRI 
examination, including stress perfusion imaging, 
after 6 months.
Clinical Outcome
The primary outcome was a composite of major 
adverse cardiac events (death from any cause, 
nonfatal myocardial infarction, or target-vessel 
revascularization) at 12 months.11 Each compo-
nent of the primary outcome was analyzed sepa-
rately as a secondary outcome. The frequency of 
invasive coronary angiography that was not per-
formed according to the protocol was assessed. 
Members of an independent clinical-events com-
mittee adjudicated all primary and secondary 
outcome events without knowledge of the ran-
domization assignments and the results of the 
index test. Definitions of outcomes are provided 
in the Supplementary Appendix.
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Characteristic Cardiovascular-MRI Group (N = 454) FFR Group (N = 464)
Age — yr  62±10  62±9
Ejection fraction — % 61±8  60±6
Male sex — no. (%) 329 (72.5) 335 (72.2)
Body-mass index 28.7±4.6 29.4±4.7
Race — no. (%)†
White 408 (89.9) 421 (90.7)
Other  46 (10.1) 43 (9.3)
Median blood pressure (IQR) — mm Hg
Systolic  142 (127–154)  143 (129–156)
Diastolic 79 (72–86) 80 (72–87)
Cholesterol — mmol/liter
Total 4.8±2.0 4.8±1.4
HDL 1.3±0.5 1.4±0.5
LDL 2.7±1.2 2.7±1.2
Triglycerides — mmol/liter 2.2±1.5 2.2±1.5
Random glucose — mmol/liter 6.1±2.4 6.2±2.4
Current smoker — no. (%)  82 (18.1)  76 (16.4)
History — no. (%)
Diabetes 112 (24.7) 138 (29.7)
Hypertension 317 (69.8) 337 (72.6)
Cerebrovascular disease 25 (5.5) 29 (6.2)
Myocardial infarction 39 (8.6) 33 (7.1)
Previous PCI  57 (12.6) 44 (9.5)
CCS angina class — no. (%)‡
I 0 0
II 407 (89.6) 415 (89.4)
III 45 (9.9)  48 (10.3)
Missing data  2 (0.4)  1 (0.2)
NYHA heart-failure class — no. (%)§
I 249 (54.8) 247 (53.2)
II 203 (44.7) 217 (46.8)
III or IV 0 0
Missing data  2 (0.4) 0
Medication — no. (%)
ACE inhibitor 142 (31.3) 148 (31.9)
ARB  69 (15.2)  57 (12.3)
Statin 296 (65.2) 311 (67.0)
Other lipid-lowering drug  71 (15.6)  52 (11.2)
Platelet inhibitor 329 (72.5) 364 (78.4)
Pretest likelihood of CAD — %¶ 75±14 74±13
*  Plus–minus values are means ±SD. There were no significant between-group differences at baseline, except for body-mass 
 index (the weight in kilograms divided by the square of the height in meters) (P = 0.02), other lipid-lowering drugs (P = 0.05), 
and platelet inhibition (P = 0.03). To convert the values for cholesterol to milligrams per deciliter, divide by 0.02586. To con-
vert the values for triglycerides to milligrams per deciliter, divide by 0.01129. To convert the values for glucose to milligrams 
per deciliter, divide by 0.05551. Percentages may not total 100 because of rounding. ACE denotes angiotensin-converting en-
zyme, ARB angiotensin-receptor blocker, FFR fractional flow reserve, HDL high-density lipoprotein, IQR interquartile 
range, LDL low-density lipoprotein, MRI magnetic resonance imaging, and PCI percutaneous coronary intervention.
†  Race was reported by the patients.
‡  Canadian Cardiovascular Society (CCS) angina classes range from I to IV, with higher classes indicating greater limita-
tions on physical activity due to angina.
§  New York Heart Association (NYHA) heart-failure classes range from I to IV, with higher classes indicating greater disability.
¶  The pretest likelihood of coronary artery disease (CAD) was calculated according to a modified Diamond and Forrester 
score.12
Table 1. Patient Characteristics at Baseline, According to Trial Group.*
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Statistical Analysis
The sample-size calculation was based on the 
expected percentage of patients with the primary 
outcome at 1 year. A 10% incidence in the FFR 
group and a noninferiority margin of 6 per-
centage points were assumed on the basis of 
the Fractional Flow Reserve versus Angiography 
for Multivessel Evaluation (FAME) trial.4 With 
these assumptions, a sample size of 826 would 
suffice to determine noninferiority of a cardio-
vascular MRI–guided strategy as compared with 
an FFR-guided strategy with a power of at least 
80% at a one-sided level of significance of 2.5%.11 
With allowance for 10% of the patients with-
drawing, a sample size of 918 patients was cho-
sen. No interim analyses were performed.
The primary analysis was a modified intention-
to-treat analysis, including only those patients 
with complete follow-up data on major adverse 
cardiac events at 12 months (defined to include 
last follow-up within 28 days before the 12-month 
time point). An intention-to-treat analysis was 
done as a sensitivity analysis by imputation of 
events for patients with no 12-month data. No 
other imputation was performed. In addition, all 
efficacy analyses were performed on a per-proto-
col set that excluded patients with major protocol 
deviations (see the Supplementary Appendix).
The time-to-first-event analyses were per-
formed with the use of a Cox proportional-haz-
ards model and Kaplan–Meier methods on all 
randomly assigned patients as time from ran-
domization to first major adverse cardiac event. 
The primary and all secondary efficacy variables 
were analyzed descriptively. For the primary out-
come, differences in proportions and asymptotic 
95% confidence intervals were calculated to test 
for noninferiority. Fisher’s exact test was used 
for categorical data, and the log-rank test was 
used for time-to-event data. The pretest likeli-
hood of coronary artery disease was calculated 
according to a modified Diamond and Forrester 
score.12 All analyses were performed with the 
use of SAS software, version 9.4 (SAS Institute).
R esult s
Baseline Characteristics, Diagnostic 
Procedures, and Therapy
A total of 16,620 patients were assessed for eli-
gibility between December 2, 2010, and August 
8, 2015; of these, 918 were deemed to be eligible 
and enrolled in the trial. Recruitment numbers 
according to center are presented in Table S1 in 
the Supplementary Appendix; reasons for the 
exclusion of ineligible patients are shown in 
Figure S1 in the Supplementary Appendix. Pa-
tient characteristics are summarized in Table 1. 
The two groups (454 patients in the cardiovas-
cular-MRI group and 464 patients in the FFR 
group) did not differ significantly with respect 
to age, sex, or symptoms at presentation. Base-
line medications and risk factors also did not 
differ significantly between the two groups 
(Table S2 in the Supplementary Appendix).
The results of the diagnostic tests as well as 
the subsequent management strategies are shown 
in Figure 1. The percentage of patients in the 
cardiovascular-MRI group with an abnormal 
cardiovascular MRI result (≥6% of myocardium 
ischemic) and positive index angiography did not 
differ significantly from the percentage in the 
FFR group with an abnormal FFR result (FFR 
Figure 1 (facing page). Randomization and Follow-up  
of the Patients.
In the group assigned to a diagnostic strategy based 
on cardiovascular magnetic resonance imaging (MRI), 
the index cardiovascular MRI was regarded as positive 
when the stress perfusion scan showed clinically signif-
icant inducible ischemia, defined as involving any of 
the following: two or more neighboring segments, two 
adjacent slices, or a single transmural segment. The 
 index angiogram in the cardiovascular-MRI group was 
visually interpreted by the performing consultant as 
positive or negative. Of the 184 patients with a posi-
tive angiogram in the cardiovascular-MRI group, 67 had 
single-vessel disease, 58 had two-vessel disease, and 
59 had triple-vessel disease. In the group assigned to  
a diagnostic strategy based on fractional flow reserve 
(FFR), FFR was performed in all coronary arteries with 
a caliber of 2.5 mm or more and a stenosis severity of 
40% or more, if technically feasible. Total occlusions 
were deemed to be FFR-positive. Revascularization was 
recommended in all vessels with an FFR of 0.8 or less. 
Of the 282 patients with a positive angiogram in the 
FFR group, 52 were classified as not having hemody-
namically significant stenoses on the basis of 93 FFR 
interrogations. Of the remaining 230 patients, 118 had 
single-vessel disease, 75 had two-vessel disease, and 
37 had triple-vessel disease. Inconsistent data were de-
fined as any database entry not logically possible (e.g., 
revascularization before recruitment or an outcome 
event before recruitment). PCI denotes percutaneous 
coronary intervention.
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 918 Underwent randomization
16,620 Patients were assessed for eligibility
15,702 Were not recruited
454 Were assigned to undergo index cardiovascular
MRI (cardiovascular-MRI group)
464 Were assigned to undergo index invasive
angiography (FFR group)
221 Had positive
test
224 Had negative
test
9 Did not undergo
cardiovascular MRI
282 Had positive
test
221 Were assigned to
undergo invasive
angiography
282 Were assigned
to undergo FFR
167 Had negative
test
15 Did not undergo
invasive angiography
184 Had positive test
162 Underwent revascularization
103 Underwent PCI
59 Underwent bypass surgery
22 Received guideline-directed medical
therapy
16 Had technical reasons (e.g., chronic
total occlusion)
3 Were advised by consultant
3 Had preference 
35 Had negative test and received guideline-
directed medical therapy
2 Did not undergo invasive angiography
and received guideline-directed medical
therapy
213 Had positive test
198 Underwent revascularization
127 Underwent PCI
71 Underwent bypass surgery
15 Received guideline-directed medical
therapy
12 Had technical reasons
1 Was advised by consultant
2 Had preference 
52 Had negative test
2 Underwent revascularization
2 Underwent PCI for symptomatic
relief
50 Received guideline-directed medical 
therapy
17 Did not undergo FFR
9 Underwent revascularization
5 Underwent PCI
4 Underwent bypass surgery
8 Received guideline-directed medical
therapy
33 Were lost to follow-up without major
adverse cardiac event
5 Had inconsistent data
3 Withdrew consent
25 Could not be contacted after 12 mo
34 Were lost to follow-up without major
adverse cardiac event
3 Had inconsistent data
9 Withdrew consent
22 Could not be contacted after 12 mo
454 Were included in the intention-to-treat
analysis
421 Were included in the modified intention-
to-treat analysis
386 Were included in the per-protocol analysis
464 Were included in the intention-to-treat
analysis
430 Were included in the modified intention-
to-treat analysis
381 Were included in the per-protocol analysis
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≤0.8): 184 patients (40.5%) in the cardiovascular-
MRI group and 213 patients (45.9%) in the FFR 
group (P = 0.11). The percentage of patients who 
underwent index revascularization was lower in 
the cardiovascular-MRI group than in the FFR 
group (162 [35.7%] vs. 209 [45.0%], P = 0.005). In 
those patients in the cardiovascular-MRI group 
who underwent invasive angiography, the medi-
an ischemic burden was 18% (interquartile range, 
12 to 27).
Follow-up
The median follow-up was 375 days (interquartile 
range, 366 to 394). There were marked reduc-
tions from baseline in blood-pressure and lipid 
levels (Table S2 in the Supplementary Appendix), 
with no significant differences between the two 
groups. After 1 year, more patients in both 
groups were receiving angiotensin-converting–
enzyme inhibitors or angiotensin-receptor block-
ers (46.5% in the cardiovascular-MRI group and 
44.2% in the FFR group at baseline vs. 53.3% and 
56.3%, respectively, at 1 year) and lipid-lowering 
therapy (78.0% in the cardiovascular-MRI group 
and 77.2% in the FFR group at baseline vs. 87.4% 
and 87.8%, respectively, at 1 year). A total of 67 
patients (7.3%) were lost to follow-up by 1 year 
before an outcome event had occurred. Reasons 
for loss to follow-up are specified in Figure 1.
Primary Outcome
The primary outcome of major adverse cardiac 
events at 1 year occurred in 15 of 421 patients 
(3.6%) in the cardiovascular-MRI group and in 
16 of 430 patients (3.7%) in the FFR group (risk 
difference, −0.2 percentage points; 95% confi-
dence interval [CI], −2.7 to 2.4; noninferiority 
margin, 6 percentage points) (Table 2). In the 
time-to-first-event analysis, the hazard ratio was 
0.96 (95% CI, 0.47 to 1.94; P = 0.91) in an un-
stratified analysis and 0.94 (95% CI, 0.46 to 1.92; 
P = 0.87) with stratification according to center 
Outcome
Cardiovascular-MRI 
Group
FFR 
Group
Risk Difference or 
Hazard Ratio (95% CI)
Primary outcome: major adverse cardiac event (modified ITT 
 analysis, unstratified)†
No. of patients with event/total no. (%) 15/421 (3.6) 16/430 (3.7) −0.2 (−2.7 to 2.4)‡
No. of total events  16§   19§
Secondary outcomes (ITT population, time-to-first-event analyses, 
unstratified)
No. of patients evaluated 454 464
Major adverse cardiac event — no. of patients   15¶   16¶ 0.96 (0.47 to 1.94)
Death
From any cause    4¶    2¶ 2.05 (0.38 to 11.21)
From cardiac cause    2¶    2¶ 1.03 (0.15 to 7.29)
Nonfatal myocardial infarction
No. of patients with event    9¶   10¶ 0.84 (0.35 to 2.02)
Total no. of events   9  10
Target-vessel revascularization
No. of patients with event    3¶    7¶ 0.34 (0.09 to 1.26)
Total no. of events   3   7
*  Major adverse cardiac events were a composite of death, nonfatal myocardial infarction, or target-vessel revascularization. ITT denotes in-
tention to treat.
†  The analysis was limited to patients with 12 months of follow-up (lower accepted time window, −28 days).
‡  Shown is the risk difference in percentage points. The other values in this column are hazard ratios.
§  Four patients had multiple events, so the number of total events is higher than the number of patients with events.
¶  No median time to event is provided because the median was not reached.
Table 2. Primary and Secondary Outcomes.*
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and sex. The Kaplan–Meier curves for event-free 
survival are shown in Figure 2. Results of the 
sensitivity analysis that was performed on an 
intention-to-treat basis, as well as the per-proto-
col analysis, were similar to those of the pri-
mary analysis (Table S3 in the Supplementary 
Appendix).
Secondary and Exploratory Outcomes
The secondary outcomes for each component of 
the primary outcome are summarized in Table 2, 
with a detailed description of the patients who 
died provided in Table S4 in the Supplementary 
Appendix. The occurrence of events according to 
the results of the index test and the performance 
of revascularization is shown in Figure 3. There 
was a significant reduction in the average CCS 
class in both groups from baseline to 1 year 
(Table S5 in the Supplementary Appendix). The 
percentage of patients free from angina after 12 
months did not differ significantly between the 
cardiovascular-MRI group (49.2%) and the FFR 
group (43.8%) (P = 0.21).
There were 31 angiograms that were not per-
formed according to the protocol during the 
follow-up period (19 in the cardiovascular-MRI 
group [4.2% of patients] and 12 in the FFR group 
[2.6% of patients], P = 0.14), resulting in 8 revas-
cularizations not performed according to the pro-
tocol in the cardiovascular-MRI group (3 target-
vessel revascularizations and 5 non–target-vessel 
revascularizations) and 8 in the FFR group 
(7 target-vessel revascularizations and 1 non–
target-vessel revascularization) (Fig. S2 in the 
Supplementary Appendix). The other protocol-
specified secondary outcomes that are not re-
ported in this article are listed in Table S6 in the 
Supplementary Appendix. Serious adverse events, 
which occurred in similar numbers of patients 
in each group, are presented in Table S7 in the 
Supplementary Appendix.
Discussion
In the MR-INFORM trial, we found that, in pa-
tients with stable angina and risk factors for 
coronary artery disease, the use of myocardial-
perfusion cardiovascular MRI in guiding initial 
management of patient care was noninferior to 
the use of invasive coronary angiography com-
bined with FFR with respect to the primary out-
come of major adverse cardiac events at 1 year. 
The use of cardiovascular MRI was associated 
with a significantly lower incidence of invasive 
coronary angiography and coronary revascular-
ization than was the use of FFR. Only 48.2% of 
the patients in the cardiovascular-MRI group 
underwent invasive angiography (as compared 
with 96.8% of those in the FFR group) despite a 
pretest likelihood for coronary artery disease of 
75%. Furthermore, 35.7% of the patients in the 
cardiovascular-MRI group, as compared with 
45.0% of those in the FFR group, underwent 
index revascularization.
Current guidelines on the management of the 
care of patients with suspected coronary artery 
disease separate diagnostic strategies from ther-
apeutic strategies owing to a lack of evidence 
comparing combined diagnostic and therapeutic 
pathways.13 The MR-INFORM trial closes this 
knowledge gap by comparing two frequently 
used, well-defined, standardized, and validat-
ed9,14-18 clinical management strategies. The car-
diovascular-MRI methods used in this trial are 
readily available and can be implemented on 
standard MRI systems.
The benefits of revascularization in patients 
with angina, clinically significant myocardial 
Figure 2. Kaplan–Meier Analysis of Event-free Survival.
The graph shows the unadjusted Kaplan–Meier estimates of patients sur-
viving free from the primary composite outcome (death from any cause, 
nonfatal myocardial infarction, or target-vessel revascularization). The inset 
shows the same data on an expanded y axis.
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ischemia, or hemodynamically relevant coronary 
artery disease are contested.19-21 Therefore, one 
limitation of the MR-INFORM trial is the lack of 
a third group of patients randomly assigned to 
medical therapy without planned revasculariza-
tion. The ongoing International Study of Com-
parative Health Effectiveness with Medical and 
Invasive Approaches (ISCHEMIA) is designed to 
answer the question of the need for revascular-
ization in patients with an intermediate-to-severe 
burden of myocardial ischemia.22 It is notable 
that three of four deaths from cardiac causes in 
the current trial occurred in patients with severe 
ischemia on the index examination while on the 
waiting list for bypass surgery, with one death 
from cardiac causes occurring in a patient who 
had a myocardial infarction before index angi-
ography.
The most important limitation of the trial is 
that the incidences of outcome events at 1 year 
Figure 3. Primary Outcome Events.
The figure shows the group assignment, test results, and subsequent therapy for all events. Five events occurred in patients who received 
guideline-directed medical therapy despite a positive index test: two in patients in the cardiovascular-MRI group who were on the wait-
ing list for bypass surgery, two in patients in the FFR group who were on the waiting list for bypass surgery, and one in a patient in the 
FFR group who had a chronic total occlusion that was not amenable to revascularization. TVR denotes target-vessel revascularization.
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were lower than expected on the basis of data 
from the FAME trial (which enrolled only pa-
tients with documented multivessel disease).4 As 
a result, the noninferiority margin was large 
relative to the incidence of major adverse cardiac 
events. Thus, noninferiority of cardiovascular 
MRI would have been shown even if the inci-
dence was twice as high as that in the FFR 
group. The actual incidences in the two groups, 
however, were similar.
No evidence of ischemia was required to pro-
ceed to target-vessel revascularization. This may 
have caused some bias since interventional car-
diologists may have had greater confidence in 
one index examination over the other. Similarly, 
a bias toward revascularization in the FFR group 
cannot be fully ruled out, since conversion from 
a diagnostic to a therapeutic procedure was 
easier in this group.
Additional limitations should also be consid-
ered. Systematic maximization of antianginal 
therapy was not performed before screening for 
enrollment, so patients who might have been 
asymptomatic after medication adjustment may 
have been enrolled in the trial. The follow-up 
period of 1 year may mask some longer-term 
differences between the strategies. The patient 
population was primarily male and white. The 
results cannot be extrapolated to other tests for 
myocardial ischemia or the functional significance 
of a coronary artery stenosis because of differ-
ences in diagnostic performance as compared 
with myocardial-perfusion cardiovascular MRI.
In conclusion, in patients with stable angina 
and risk factors for coronary artery disease, an 
initial management strategy guided by myocar-
dial-perfusion cardiovascular MRI was noninfe-
rior to a strategy of invasive angiography and 
FFR with regard to major adverse cardiac events 
at 12 months.
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